Zacks Investment Research

Selected news for the capital firm - Zacks Investment Research, collected since 10/2017. This capital firm shares healthcare news with Oncology, Medical Research, Biotech, Wolfe Research, Biopharma and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/12/2022 Community Health Systems (NYSE:CYH) Stock Price Up 2.7% thelincolnianonline.com ... of Community Health Systems from an “underperform” rating to a “buy” rating and lifted their price objective for the stock from $14.00 to $16.00 in a research note on Monday, December 13th. Zacks Investment Research raised shares of Community Health Systems from a “hold” rating to a “strong-buy” rating and set a $14.00 price objective on the stock in a research note on Friday, October ...
1/12/2022 Electromed (NYSEAMERICAN:ELMD) Rating Lowered to Hold at Zacks Investment Research zolmax.com Electromed (NYSEAMERICAN:ELMD) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports.According to Zacks, “Electromed, Inc. manufactures, markets and sells products that provide airway clearance therapy to patients with compromised pulmonary function. The Company is the designer, manufacturer and worldwide provider of the SmartVest® Airway Clearance System and related products. The patented system ...
1/12/2022 Electromed (NYSEAMERICAN:ELMD) Rating Lowered to Hold at Zacks Investment Research zolmax.com Electromed (NYSEAMERICAN:ELMD) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports.According to Zacks, “Electromed, Inc. manufactures, markets and sells products that provide airway clearance therapy to patients with compromised pulmonary function. The Company is the designer, manufacturer and worldwide provider of the SmartVest® Airway Clearance System and related products. The patented system ...
1/12/2022 Zacks Investment Research Lowers Apyx Medical (NASDAQ:APYX) to Sell - Ticker Report Ticker Report ... Equipment Manufacture (OME).Read More: What is the formula for the cash asset ratio?Get a free copy of the Zacks research report on Apyx Medical (APYX)For more information about research offerings from Zacks Investment Research , visit Zacks.com ...
1/12/2022 AdaptHealth (NASDAQ:AHCO) Lowered to Hold at Zacks Investment Research com-unik.info AdaptHealth (NASDAQ:AHCO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Monday, Zacks.com reports.According to Zacks, “AdaptHealth Corp. is a provider of home medical equipment primarily in the United States. It offers medical products for both rental and sale, with a focus on respiratory and/or mobility equipment, including CPAP sleep equipment, oxygen equipment, wheelchairs ...
1/12/2022 Inspire Medical Systems (NYSE:INSP) Stock Rating Upgraded by Zacks Investment Research dispatchtribunal.com Inspire Medical Systems (NYSE:INSP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The firm currently has a $255.00 price target on the stock. Zacks Investment Research ‘s target price would suggest a potential upside of 9.61% from the stock’s current price.According to Zacks, “Inspire Medical Systems Inc. is a medical ...
1/12/2022 Inspire Medical Systems (NYSE:INSP) Rating Increased to Buy at Zacks Investment Research thelincolnianonline.com Inspire Medical Systems (NYSE:INSP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday, Zacks.com reports. The brokerage presently has a $255.00 target price on the stock. Zacks Investment Research ‘s price target would indicate a potential upside of 9.61% from the stock’s current price.According to Zacks, “Inspire Medical Systems Inc. is a medical technology ...
1/12/2022 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Expected to Post Earnings of -$0.25 Per Share - Watch List News watchlistnews.com ... year, with EPS estimates ranging from ($1.15) to ($0.92). For the next financial year, analysts anticipate that the company will post earnings of ($0.97) per share, with EPS estimates ranging from ($1.27) to ($0.62). Zacks Investment Research ’s earnings per share averages are an average based on a survey of research firms that follow ACADIA Pharmaceuticals.Get ACADIA Pharmaceuticals alerts: ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data ...
1/12/2022 Alto Ingredients (NASDAQ:ALTO) Upgraded to “Hold” by Zacks Investment Research theenterpriseleader.com Alto Ingredients (NASDAQ:ALTO) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports.According to Zacks, “Alto Ingredients Inc. is a producer of specialty alcohols and essential ingredients. The company is focused on products which includes Health, Home & Beauty; Food & Beverage; Essential Ingredients and Renewable Fuels. Alto Ingredients Inc., formerly known as Pacific Ethanol ...
1/12/2022 Weekly Analysts’ Ratings Updates for Citizens & Northern (CZNC) rivertonroll.com Several analysts have recently updated their ratings and price targets for Citizens & Northern (NASDAQ: CZNC):- 1/5/2022 – Citizens & Northern was upgraded by analysts at [Zacks Investment Research] from a “hold” rating to a “buy” rating. They now have a $29.00 price target on the stock. According to Zacks, “Citizens & Northern Corporation is a one-bank holding company whose principal subsidiary is Citizens & Northern Bank. The Corporation’s principal ...
1/12/2022 Clover Health Investments (NASDAQ:CLOV) Stock Rating Upgraded by Zacks Investment Research Daily Political Clover Health Investments (NASDAQ:CLOV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Clover Health Investments Corp. is a healthcare technology company. It uses its proprietary technology platform to collect, structure and analyze health and behavioral data to improve medical outcomes and lower costs for patients. Clover Health Investments ...
1/12/2022 Weekly Analysts’ Ratings Updates for Citizens & Northern (CZNC) - Slater Sentinel slatersentinel.com Several analysts have recently updated their ratings and price targets for Citizens & Northern (NASDAQ: CZNC):1/5/2022 – Citizens & Northern was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $29.00 price target on the stock. According to Zacks, “Citizens & Northern Corporation is a one-bank holding company whose principal subsidiary is Citizens & Northern Bank. The Corporation’s principal ...
1/12/2022 Clover Health Investments (NASDAQ:CLOV) Raised to “Hold” at Zacks Investment Research zolmax.com Clover Health Investments (NASDAQ:CLOV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.According to Zacks, “Clover Health Investments Corp. is a healthcare technology company. It uses its proprietary technology platform to collect, structure and analyze health and behavioral data to improve medical outcomes and lower costs for patients ...
1/12/2022 Cytokinetics (NASDAQ:CYTK) Raised to “Buy” at Zacks Investment Research - Watch List News watchlistnews.com Cytokinetics (NASDAQ:CYTK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, Zacks.com reports. The brokerage presently has a $40.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research ‘s price objective points to a potential upside of 14.88% from the stock’s previous close.According to Zacks, “Cytokinetics is a late-stage ...
1/12/2022 Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Zacks Investment Research theenterpriseleader.com Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday, Zacks.com reports. The firm presently has a $14.00 target price on the biotechnology company’s stock. Zacks Investment Research ‘s price target points to a potential upside of 8.44% from the company’s previous close.According to Zacks, “Aclaris Therapeutics, Inc. is a ...
1/12/2022 GoodRx (NASDAQ:GDRX) Stock Rating Upgraded by Zacks Investment Research dispatchtribunal.com GoodRx (NASDAQ:GDRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.According to Zacks, “GoodRx Holdings Inc. provides consumer-focused digital healthcare platform. GoodRx Holdings Inc. is based in Santa Monica, California. “Several other brokerages have also weighed in on GDRX. The Goldman Sachs Group initiated coverage on ...
1/12/2022 GoodRx (NASDAQ:GDRX) Stock Rating Upgraded by Zacks Investment Research thelincolnianonline.com GoodRx (NASDAQ:GDRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports.According to Zacks, “GoodRx Holdings Inc. provides consumer-focused digital healthcare platform. GoodRx Holdings Inc. is based in Santa Monica, California. “A number of other equities research analysts have also issued reports on GDRX. Jefferies Financial Group started coverage on GoodRx in ...
1/12/2022 $20.98 Million in Sales Expected for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) This Quarter - Ticker Report Ticker Report Wall Street analysts predict that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will announce $20.98 million in sales for the current fiscal quarter, according to Zacks Investment Research . Three analysts have provided estimates for AVEO Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $16.38 million and the highest estimate coming in at $23.76 million. AVEO Pharmaceuticals posted sales of $890,000.00 during the same quarter last year, which suggests a ...
1/12/2022 Zogenix (NASDAQ:ZGNX) Downgraded to Sell at Zacks Investment Research - Slater Sentinel slatersentinel.com ... MT1621. The company was founded by Stephen James Farr, Cam L.Featured Article: Momentum InvestingGet a free copy of the Zacks research report on Zogenix (ZGNX)For more information about research offerings from Zacks Investment Research, visit Zacks.com ...
1/12/2022 Zacks Investment Research Lowers Zogenix (NASDAQ:ZGNX) to Sell - Transcript Daily transcriptdaily.com ... company was founded by Stephen James Farr, Cam L.Featured Story: Growth and Income FundsGet a free copy of the Zacks research report on Zogenix (ZGNX)For more information about research offerings from Zacks Investment Research , visit Zacks.comReceive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's ...